4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)

4 - Channel Therapeutics Corp (0001919246) (Issuer)

4 - Channel Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4 - Chromocell Therapeutics Corp (0001919246) (Issuer)

4/A - Chromocell Therapeutics Corp (0001919246) (Issuer)

SCHEDULE 13D/A - Pelthos Therapeutics Inc. (0001919246) (Subject)

SCHEDULE 13D - Pelthos Therapeutics Inc. (0001919246) (Subject)

8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)

DEFM14C - Channel Therapeutics Corp (0001919246) (Filer)

10-Q - Channel Therapeutics Corp (0001919246) (Filer)

PREM14C - Channel Therapeutics Corp (0001919246) (Filer)

8-K - Channel Therapeutics Corp (0001919246) (Filer)

8-K - Channel Therapeutics Corp (0001919246) (Filer)

10-K - Channel Therapeutics Corp (0001919246) (Filer)

8-K - Channel Therapeutics Corp (0001919246) (Filer)

The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, today announced a 10-for-one reverse split (the "Reverse Stock Split") of the Company's common stock (the "Common Stock"). The Reverse Stock Split is intended to increase the market price per share of the Company's Common Stock and help the Company satisfy the initial listing requirements of the NYSE American (the "NYSE American") in connection with the anticipated closing of the previously announced merger of CHRO Merger Sub, Inc., a wholly owned subsidiary of the Company, with and in

FREEHOLD, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has achieved its predefined endpoints in two pre-clinical animal models of the Company's eye drop formulations ("CT2000") for the treatment of both acute ocular pain as well as chronic ocular surface pain commonly associated with dry eye disease. "We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results announced in December 2024, demonstrating a viable path forward in treating both post-surgical pain and ch

FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today advises that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on March 27, 2025, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included a going concern emphasis of matter paragraph. Release of this information is required by Sections 410(h) and 610(b) of the NYSE American LLC Company Guide. This announcement does not rep

Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI™ ZELSUVMI is an FDA-designated novel drug and the first and only prescription medication approved for the treatment of Molluscum contagiosum infections administered at home by parents, patients, and caregivers Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI Transaction is expected to close in the summer of 2025 JUPITER, Fla. and FREEHOLD, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated ("Ligand") (NASDAQ:LGND) and Channel Therapeutics Corporation ("Channel") (NYSE:CHRO), a pioneer i

FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, is providing a statement regarding Vertex Pharmaceutical's recently announced Phase 2 data of Suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy. "We are encouraged to see that the product will advance to Phase 3 trials in painful lumbosacral radiculopathy, pending discussions with regulators," said Eric Lang, Channel's Chief Medical Officer. "While both NaV1.7 and NaV1.8 are voltage-gated sodium channels mainly

FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it achieved its endpoints in two pre-clinical in vivo models of the Company's nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration. "We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain," stated Dr. Eric Lang, Chief Medical Officer of Channel. "Addi

"Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts FREEHOLD, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation, (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that on November 18, 2024 it had changed its name to Channel Therapeutics Corporation ("Channel" or the "Company"), along with reincorporating in the State of Nevada. The Company believes the name change better reflects its focus on developing therapeutics based on sodium channel modulation and blockade for

FREEHOLD, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-operative pain. The depot program is based on the Company's novel NaV1.7 molecule for treating chronic pain and eye pain. There are approximately 700,000 total knee replacements and 500,000 shoulder arthroplasties performed annually in the Unites States for which this analgesic modality might be applicable, providing a robust potential market for the product. "We are

FREEHOLD, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation ("Chromocell", or the "Company"), (NYSE:CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that Frank Knuettel II, CEO, will present at the upcoming LDMicro and Spartan Capital investor conferences. Details for the conferences and presentations are as follows: LDMicro Main Event XVII (October 28-30, 2024) Presentation: October 29, 2024 Time: 10:00 AM - 10:25 AM PTLocation: Luxe Sunset BLVD Hotel, Los AngelesIn-person registration: LINKVirtual attendance: LINKAvailable for 1x1 meetings: October 29th The Main Event has become the industry stand

The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me

SC 13G/A - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13G - Chromocell Therapeutics Corp (0001919246) (Subject)

SC 13D - Chromocell Therapeutics Corp (0001919246) (Subject)